Literature DB >> 18463957

Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer.

Yutaka Yonemura1, Cheng-Chung Wu, Norimasa Fukushima, Ichirou Honda, Etsurou Bandou, Taiichi Kawamura, Tohru Kamata, Byung-Sik Kim, Nobuo Matsuki, Toshiharu Sawa, Sung-Hoon Noh.   

Abstract

BACKGROUND: The survival of patients with advanced gastric cancer after D2 dissection is still poor. Asian surgeons have proposed a more radical lymph node dissection, designated as D4 dissection, where paraaortic lymph nodes are removed in combination with D2 dissection. To evaluate the survival benefit of D4 dissection, a multi-institutional randomized trial of D2 vs D4 gastrectomy was conducted.
METHODS: Patients enrolled in the study had potentially curable gastric adenocarcinoma at an advanced stage. Patients were randomized to undergo either D2 or D4 gastrectomy.
RESULTS: Two hundred and ninety-three patients were registered and 269 patients were eligible; 135 patients were allocated to the D2 group and 134 to the D4 group. Five-year survival was 52.6% after D2 surgery and 55.0% after D4 gastrectomy. There was no significant difference in survival between the D2 and D4 groups (chi(2) = 0.064; P = 0.801). Hospital deaths occurred in 1 patients (0.7%) in the D2 group and 5 in the D4 group D4 gastrectomy is a more risky surgery than D2 dissection. Seven patients (5.2%) in the D2 and 15 (11.2%) in the D4 group died of causes other than gastric cancer recurrence. Sixty-three patients (46.7%) in the D2 group and 52 (38.8%) in the D4 group had disease recurrence.
CONCLUSION: Prophylactic D4 dissection is not recommended for patients with potentially curable advanced gastric cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18463957     DOI: 10.1007/s10147-007-0727-1

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  17 in total

1.  Nodal dissection for patients with gastric cancer: a randomised controlled trial.

Authors:  Chew-Wun Wu; Chao A Hsiung; Su-Shun Lo; Mao-Chin Hsieh; Jen-Hao Chen; Anna Fen-Yau Li; Wing-Yiu Lui; Jacqueline Whang-Peng
Journal:  Lancet Oncol       Date:  2006-04       Impact factor: 41.316

2.  Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study.

Authors:  D H Roukos; M Lorenz; A Encke
Journal:  Surgery       Date:  1998-05       Impact factor: 3.982

3.  Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group.

Authors:  A Cuschieri; P Fayers; J Fielding; J Craven; J Bancewicz; V Joypaul; P Cook
Journal:  Lancet       Date:  1996-04-13       Impact factor: 79.321

4.  Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients.

Authors:  J J Bonenkamp; I Songun; J Hermans; M Sasako; K Welvaart; J T Plukker; P van Elk; H Obertop; D J Gouma; C W Taat
Journal:  Lancet       Date:  1995-03-25       Impact factor: 79.321

5.  The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification.

Authors:  T Kajitani
Journal:  Jpn J Surg       Date:  1981-03

6.  [Superextended lymphadenectomy (D4) in the treatment of gastric adenocarcinoma].

Authors:  A Di Leo; C Pedrazzani; M Bonfiglio; G Borzellino; G Zerman; S Tasselli; G De Manzoni
Journal:  Minerva Chir       Date:  2002-10       Impact factor: 1.000

7.  Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial.

Authors:  H H Hartgrink; C J H van de Velde; H Putter; J J Bonenkamp; E Klein Kranenbarg; I Songun; K Welvaart; J H J M van Krieken; S Meijer; J T M Plukker; P J van Elk; H Obertop; D J Gouma; J J B van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus; M Sasako
Journal:  J Clin Oncol       Date:  2004-04-13       Impact factor: 44.544

8.  Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501.

Authors:  Takeshi Sano; Mitsuru Sasako; Seiichiro Yamamoto; Atsushi Nashimoto; Akira Kurita; Masahiro Hiratsuka; Toshimasa Tsujinaka; Taira Kinoshita; Kuniyoshi Arai; Yoshitaka Yamamura; Kunio Okajima
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

9.  Influence of the extent of resection on survival after curative treatment of gastric carcinoma. A retrospective multivariate analysis.

Authors:  M H Shiu; E Moore; M Sanders; A Huvos; B Freedman; J Goodbold; S Chaiyaphruk; R Wesdorp; M F Brennan
Journal:  Arch Surg       Date:  1987-11

10.  Surgical results of performing R4 gastrectomy for gastric cancer located in the upper third of the stomach.

Authors:  Y Yonemura; M Segawa; H Matsumoto; K Tsugawa; I Ninomiya; L Fonseca; T Fujimura; K Sugiyama; K Miwa; I Miyazaki
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

View more
  29 in total

Review 1.  Gastric adenocarcinoma with para-aortic lymph node metastasis: a borderline resectable cancer?

Authors:  Yasuhiro Kodera; Daisuke Kobayashi; Chie Tanaka; Michitaka Fujiwara
Journal:  Surg Today       Date:  2014-11-01       Impact factor: 2.549

Review 2.  Systematic review of D2 lymphadenectomy versus D2 with para-aortic nodal dissection for advanced gastric cancer.

Authors:  Zhen Wang; Jun-Qiang Chen; Yun-Fei Cao
Journal:  World J Gastroenterol       Date:  2010-03-07       Impact factor: 5.742

Review 3.  Para-aortic lymphadenectomy in surgery for gastric cancer: current indications and future perspectives.

Authors:  Valentina Mengardo; Maria Bencivenga; Jacopo Weindelmayer; Michele Pavarana; Simone Giacopuzzi; Giovanni de Manzoni
Journal:  Updates Surg       Date:  2018-05-30

Review 4.  Lymphadenectomy in gastric cancer: Contentious issues.

Authors:  Pankaj Kumar Garg; Ashish Jakhetiya; Jyoti Sharma; Mukur Dipi Ray; Durgatosh Pandey
Journal:  World J Gastrointest Surg       Date:  2016-04-27

Review 5.  A systematic review of spleen and pancreas preservation in extended lymphadenectomy for gastric cancer.

Authors:  Savtaj S Brar; Rajini Seevaratnam; Roberta Cardoso; Calvin Law; Lucy Helyer; Natalie Coburn
Journal:  Gastric Cancer       Date:  2011-09-14       Impact factor: 7.370

6.  Surgical care quality and oncologic outcome after D2 gastrectomy for gastric cancer.

Authors:  Johanna Mrena; Anne Mattila; Jan Böhm; Ismo Jantunen; Ilmo Kellokumpu
Journal:  World J Gastroenterol       Date:  2015-12-21       Impact factor: 5.742

7.  Lymphadenectomy with Optimum of 29 Lymph Nodes Retrieved Associated with Improved Survival in Advanced Gastric Cancer: A 25,000-Patient International Database Study.

Authors:  Yanghee Woo; Bryan Goldner; Philip Ituarte; Byrne Lee; Laleh Melstrom; Taeil Son; Sung Hoon Noh; Yuman Fong; Woo Jin Hyung
Journal:  J Am Coll Surg       Date:  2016-12-23       Impact factor: 6.113

8.  Paraaortic lymph node metastasis in patients with intra-abdominal malignancies: CT vs PET.

Authors:  Mi-Jung Lee; Mi Jin Yun; Mi-Suk Park; Seung Hwan Cha; Myeong-Jin Kim; Jong Doo Lee; Ki Whang Kim
Journal:  World J Gastroenterol       Date:  2009-09-21       Impact factor: 5.742

Review 9.  Extent of lymphadenectomy and perioperative therapies: two open issues in gastric cancer.

Authors:  Andrea Giuliani; Michelangelo Miccini; Luigi Basso
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

10.  Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.

Authors:  Stephen R Smalley; Jacqueline K Benedetti; Daniel G Haller; Scott A Hundahl; Norman C Estes; Jaffer A Ajani; Leonard L Gunderson; Bryan Goldman; James A Martenson; J Milburn Jessup; Grant N Stemmermann; Charles D Blanke; John S Macdonald
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.